Acute Myeloid Leukemia
Conditions
Keywords
AML
Brief summary
This is a prospective, observational study to collect stool and blood from acute myeloid leukemia patients undergoing intensive chemotherapy.
Interventions
Collected from each patient twice weekly.
Collected from each patient twice weekly.
Sponsors
Study design
Eligibility
Inclusion criteria
* Adults (ages 18 - 99 years) undergoing inpatient intensive chemotherapy for newly diagnosed, refractory, or relapsed AML. Patients may or may not have been exposed to any type of therapy before. * Any intensive chemotherapy regimen defined as a planned \ 4 week inpatient stay. Chemotherapy may be delivered for any number of days and on any schedule. Patients may be discharged from the hospital sooner than 4 weeks if the treating physician choose so, but the expectation at the initiation of chemotherapy must be \ 4 weeks of inpatient stay, as is typical. * Able to provide written voluntary consent before performance of any study related procedure.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Abundance of Phyla | Day 28 | Abundance in stool and circulating microbiota during intensive chemotherapy in patients with acute myeloid leukemia (AML), measured by16S rRNA gene profiling of biospecimens using the Illumina MiSeq platform |
| Abundance of Genera | Day 28 | Abundance in stool and circulating microbiota during intensive chemotherapy in patients with acute myeloid leukemia (AML), measured by16S rRNA gene profiling of biospecimens using the Illumina MiSeq platform |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Circulating Microbiota Diversity (Blood) | Day 28 | Describe circulating microbiota diversity over the course of treatment |
| Microbiota Diversity (Stool) | Day 28 | Describe stool microbiota diversity over the course of treatment |
Countries
United States